Anny Shai

Title(s)Associate Director, Neurological Surgery
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. NIMG-22. COMPARISON OF NON-INVASIVE, ML-GENERATED WHOLE-BRAIN SPATIAL RADIOPATHOMIC MAPS DERIVED FROM ANATOMICAL AND DIFFUSION-WEIGHTED MRI ON PATIENTS WITH NEWLY DIAGNOSED-GLIOMA. Neuro-Oncology. 2023 Nov 10; 25(Supplement_5):v189-v190. Adegbite AO, Tran TN, Molinaro MA, Phillips PJ, LaViolette LP, Bobholz BS, Ellison EJ, Li LY, Luks LT, Shai SA, Nair ND, Villanueva-Meyer VJ, Connelly CJ, Berger BM, Hervey-Jumper HS, Aghi AM, Chang CS, Lupo LJ. .
      View in: Publisher Site   Mentions:
    2. EPCO-19. TUMOR-WIDE NEOANTIGEN-SPECIFIC T-CELLS INFILTRATING MUTANT IDH1 LOW-GRADE GLIOMAS AND PERSISTING IN PERIPHERAL BLOOD ALLOW FOR PERSONALIZED TCR-BASED IMMUNOTHERAPIES. Neuro-Oncology. 2023 Nov 10; 25(Supplement_5):v127-v127. Kwok KD, Zhang ZM, Wang WC, Stevers SN, Borrman BT, Pan PZ, Yuen YB, Peng PS, Nguyen ND, Martin MM, Hong HC, Hilz HS, Phillips PJ, Shai SA, Bush BN, Hervey-Jumper HS, McDermott MM, Mandl MS, Okada OH, Costello CJ. .
      View in: Publisher Site   Mentions:
    3. NIMG-64. IN VIVO METABOLIC PROFILING FOR RECURRENT GLIOMA. Neuro-Oncology. 2023 Nov 10; 25(Supplement_5):v200-v200. Li LY, Lafontaine LM, Autry AA, Jiang JF, Shai SA, Phillips PJ, Chang CS. .
      View in: Publisher Site   Mentions:
    4. PATH-08. LONGITUDINAL MOLECULAR EVOLUTION OF IDH-WILDTYPE GLIOBLASTOMA IN ADULTS. Neuro-Oncology. 2023 Nov 10; 25(Supplement_5):v168-v168. Lucas LC, Al-Adli AN, Young YJ, Morshed MR, Gupta GR, Wu WJ, Ravindranathan RA, Lee LJ, Shai SA, Bush BN, Taylor TJ, de Groot dJ, Butowski BN, Pekmezci PM, Perry PA, Bollen BA, Theodosopoulos TP, Aghi AM, Chang CE, Hervey-Jumper HS, Costello CJ, Clarke CJ, Diaz DA, Phillips PJ, Berger BM, Chang CS, Solomon SD. .
      View in: Publisher Site   Mentions:
    5. NIMG-12. SPATIALLY MAPPING TREATMENT-EFFECT IN RECURRENT GLIOMA WITH PHYSIOLOGIC MRI AND DEEP LEARNING. Neuro-Oncology. 2023 Nov 10; 25(Supplement_5):v186-v187. Ellison EJ, Tran TN, Hanna HR, Phillips PJ, Shai SA, Nair ND, Molinaro MA, Pedoia PV, Li LY, Luks LT, Villanueva-Meyer VJ, Berger BM, Hervey-Jumper HS, Aghi AM, Chang CS, Lupo LJ. .
      View in: Publisher Site   Mentions:
    6. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 2023 Sep 27. Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H. PMID: 37758193.
      View in: PubMed   Mentions:    Fields:    
    7. Abstract 895: Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies. Cancer Research. 2023 Apr 4; 83(7_Supplement):895-895. Kwok KD, Zhang ZM, Wang WC, Stevers SN, Borrman BT, Pan PZ, Yuen YB, Peng PS, Nguyen ND, Martin MM, Hong HC, Hilz HS, Phillips PJ, Shai SA, Bush BN, Hervey-Jumper HS, McDermott MM, Mandl MS, Okada OH, Costello CJ. .
      View in: Publisher Site   Mentions:
    8. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. J Clin Oncol. 2023 04 10; 41(11):2029-2042. Hervey-Jumper SL, Zhang Y, Phillips JJ, Morshed RA, Young JS, McCoy L, Lafontaine M, Luks T, Ammanuel S, Kakaizada S, Egladyous A, Gogos A, Villanueva-Meyer J, Shai A, Warrier G, Rice T, Crane J, Wrensch M, Wiencke JK, Daras M, Oberheim Bush NA, Taylor JW, Butowski N, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Jakola AS, Kavouridis VK, Nawabi N, Solheim O, Smith T, Berger MS, Molinaro AM. PMID: 36599113; PMCID: PMC10082290.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    9. NIMG-46. TOWARDS PREDICTING TUMOR AGGRESSIVENESS WITH RADIOPATHOMIC ANALYSIS OF MULTI-PARAMETRIC ANATOMICAL, DIFFUSION-WEIGHTED, AND METABOLIC MRI IN PATIENTS WITH NEWLY-DIAGNOSED GLIOMAS. Neuro-Oncology. 2022 Nov 14; 24(Supplement_7):vii173-vii174. Adegbite AO, Tran TN, Molinaro MA, Phillips PJ, Ellison EJ, Li LY, Luks LT, Shai SA, Nair ND, Pedoia PV, Villanueva-Meyer VJ, Berger BM, Hervey-Jumper HS, Aghi AM, Lupo LJ. .
      View in: Publisher Site   Mentions:
    10. PATH-07. MULTIPLATFORM MOLECULAR ANALYSES REFINE CLASSIFICATION AND PROGNOSTICATION OF GLIOMAS ARISING IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1. Neuro-Oncology. 2022 Nov 14; 24(Supplement_7):vii151-vii151. Lucas LC, Sloan SE, Jung JJ, Gupta GR, Wu WJ, Vasudevan VH, Shai SA, Whipple WN, Bruggers BC, Samuel SD, Maher MO, Lu LR, Mirchia MK, Sullivan SD, Pekmezci PM, Tihan TT, Bollen BA, Perry PA, Banerjee BA, Gupta GN, Mueller MS, de Groot dJ, Clarke CJ, Raleigh RD, Phillips PJ, Reddy RA, Chang CS, Berger BM, Diaz DA, Solomon SD. .
      View in: Publisher Site   Mentions:
    11. NIMG-65. IMPROVED SPATIAL MAPPING OF TUMOR AGGRESSIVENESS WITH 1H MAGNETIC RESONANCE SPECTROSCOPY AND DEEP LEARNING IN PATIENTS WITH NEWLY-DIAGNOSED GLIOMA. Neuro-Oncology. 2022 Nov 14; 24(Supplement_7):vii179-vii179. Tran TN, Li LY, Ellison EJ, Adegbite AO, Phillips PJ, Molinaro MA, Pedoia PV, Shai SA, Nair ND, Jakary JA, Lafontaine LM, Villanueva-Meyer VJ, Berger BM, Hervey-Jumper HS, Aghi AM, Chang CS, Lupo LJ. .
      View in: Publisher Site   Mentions:
    12. NIMG-61. IMPROVED GENERALIZABILITY OF RADIOPATHOMIC PROBABILISTIC MAPPING OF TREATMENT-INDUCED EFFECTS WITH PHYSIOLOGIC MR IMAGING AND DEEP LEARNING IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology. 2022 Nov 14; 24(Supplement_7):vii177-vii178. Ellison EJ, Tran TN, Molinaro MA, Pedoia PV, Phillips PJ, Shai SA, Nair ND, Lafontaine LM, Jakary JA, Luks LT, Villanueva-Meyer VJ, Chang CS, Berger BM, Hervey-Jumper HS, Aghi AM, Lupo LJ. .
      View in: Publisher Site   Mentions:
    13. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro Oncol. 2022 09 01; 24(9):1471-1481. Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM, Phillips JJ. PMID: 35287169; PMCID: PMC9435510.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    14. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol. 2022 Oct; 144(4):747-765. Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu R, Mirchia K, Sullivan DV, Pekmezci M, Tihan T, Bollen AW, Perry A, Banerjee A, Mueller S, Gupta N, Hervey-Jumper SL, Oberheim Bush NA, Daras M, Taylor JW, Butowski NA, de Groot J, Clarke JL, Raleigh DR, Costello JF, Phillips JJ, Reddy AT, Chang SM, Berger MS, Solomon DA. PMID: 35945463; PMCID: PMC9468105.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma. Clin Cancer Res. 2022 07 01; 28(13):2898-2910. Kumar A, Mohamed E, Tong S, Chen K, Mukherjee J, Lim Y, Wong CM, Boosalis Z, Shai A, Pieper RO, Gupta N, Perry A, Bollen AW, Molinaro AM, Solomon DA, Shieh JTC, Phillips JJ. PMID: 35511927; PMCID: PMC9250623.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    16. Abstract 3797: 3D whole tumor analysis of the TERT promoter mutation in gliomas. Cancer Research. 2022 Jun 15; 82(12_Supplement):3797-3797. Appin AC, Suwala SA, Hilz HS, Mathur MR, Smirnov SI, Hong HC, Stevers SN, Shai SA, Wang WA, Berger BM, Chang CS, Phillips PJ, Costello CJ. .
      View in: Publisher Site   Mentions:
    17. Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging. Neuro Oncol. 2022 04 01; 24(4):639-652. Cluceru J, Interian Y, Phillips JJ, Molinaro AM, Luks TL, Alcaide-Leon P, Olson MP, Nair D, LaFontaine M, Shai A, Chunduru P, Pedoia V, Villanueva-Meyer JE, Chang SM, Lupo JM. PMID: 34653254; PMCID: PMC8972294.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    18. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022 02 01; 132(3). Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. PMID: 34882581; PMCID: PMC8803342.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsPHPublic Health
    19. PATH-28. RE-DEFINING CLONALITY OF THE TERT PROMOTER MUTATION WITH DEEP SEQUENCING AND MAXIMAL SAMPLING OF NEWLY DIAGNOSED AND RECURRENT GBM AND OLIGODENDROGLIOMA. Neuro-Oncology. 2021 Nov 12; 23(Supplement_6):vi121-vi121. Appin AC, Suwala SA, Hilz HS, Mathur MR, Smirnov SI, Hong HC, Stevers SN, Shai SA, Berger BM, Chang CS, Phillips PJ, Costello CJ. .
      View in: Publisher Site   Mentions:
    20. NIMG-25. IMPROVING THE NONINVASIVE CLASSIFICATION OF GLIOMA GENETIC SUBTYPE WITH DEEP LEARNING AND DIFFUSION-WEIGHTED IMAGING. Neuro-Oncology. 2021 Nov 12; 23(Supplement_6):vi133-vi134. Cluceru CJ, Phillips PJ, Molinaro MA, Interian IY, Luks LT, Alcaide-Leon AP, Nair ND, LaFontaine LM, Shai SA, Chunduru CP, Pedoia PV, Villanueva-Meyer VJ, Chang CS, Lupo LJ. .
      View in: Publisher Site   Mentions:
    21. CTIM-24. RANDOMIZED TRIAL OF NEOADJUVANT VACCINATION WITH TUMOR-CELL LYSATE INDUCES T CELL RESPONSE IN LOW-GRADE GLIOMAS. Neuro-Oncology. 2021 Nov 12; 23(Supplement_6):vi55-vi55. Taylor TJ, Ogino OH, Nejo NT, Gibson GD, Watchmaker WP, Okada OK, Saijo SA, Tedesco TM, Shai SA, Wong WC, Rabbitt RJ, Olin OM, Moertel MC, Nishioka NY, Salazar SA, Molinaro MA, Phillips PJ, Butowski BN, Clarke CJ, Oberheim-Bush ON, Hervey-Jumper HS, Theodosopoulos TP, Chang CS, Berger BM, Okada OH. .
      View in: Publisher Site   Mentions:
    22. IMMU-33. NEOANTIGEN-SPECIFIC T CELLS CAN INFILTRATE IDH-MUTANT LOWER GRADE GLIOMAS AND PERSIST IN THE PERIPHERAL BLOOD. Neuro-Oncology. 2021 Nov 12; 23(Supplement_6):vi99-vi100. Zhang ZM, Wang WC, Pan PZ, Yuen YB, Peng PS, Kwok KD, Nejo NT, Martin MM, Hong HC, Hilz HS, Phillips PJ, Shai SA, Oberheim-Bush ON, Hervey-Jumper HS, McDermott MM, Mandl MS, Okada OH, Costello CJ. .
      View in: Publisher Site   Mentions:
    23. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021 11 02; 23(11):1872-1884. Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, Butowski N, Clarke JL, Berger MS, Molinaro AM, Chang SM, Costello JF, Oberheim Bush NA. PMID: 33823014; PMCID: PMC8563321.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    24. PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS. Neuro-Oncology. 2020 Nov 9; 22(Supplement_2):ii166-ii166. Yu YY, Villanueva-Meyer VJ, Chang CS, Grimmer GM, Hilz HS, Solomon SD, Choi CS, Wahl WM, Mazor MT, Hong HC, Shai SA, Phillips PJ, McDermott MM, Haas-Kogan HD, Taylor TJ, Butowski BN, Clarke CJ, Berger BM, Costello CJ, Bush BN. .
      View in: Publisher Site   Mentions:
    25. SURG-15. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED DIFFUSE LOW-GRADE GLIOMA. Neuro-Oncology. 2020 Nov 9; 22(Supplement_2):ii206-ii206. Hervey-Jumper HS, Molinaro MA, Phillips PJ, Morshed MR, Young YJ, Zhang ZY, LaFontaine LM, Luks LT, Ammanuel AS, Kakaizada KS, Villanueva-Meyer VJ, Shai SA, Warrier WG, Rice RT, Lin LY, Crane CJ, Wrensch WM, Wiencke WJ, Bush BN, Taylor TJ, Butowski BN, Clarke CJ, Chang CS, Chang CE, Aghi AM, Theodosopoulos TP, Berger BM. .
      View in: Publisher Site   Mentions:
    26. SURG-18. THE IMPACT OF NEUROLOGIC IMPAIRMENTS ON THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION IN NEWLY DIAGNOSED IDH-WILD TYPE GLIOBLASTOMA. Neuro-Oncology. 2020 Nov 9; 22(Supplement_2):ii207-ii207. Hervey-Jumper HS, Molinaro MA, Ore OC, Brown BD, Zhang ZY, Morshed MR, LaFontaine LM, Ammanuel AS, Shai SA, Warrier WG, Rice RT, Lin LY, Crane CJ, Phillips PJ, Wrensch WM, Wiencke WJ, Bush BN, Taylor TJ, Butowski BN, Clarke CJ, Chang CS, Aghi AM, Theodosopoulos TP, Berger BM. .
      View in: Publisher Site   Mentions:
    27. BIOM-38. PI3K/AKT/mTOR SIGNALING PATHWAY ACTIVITY IN IDH-MUTANT DIFFUSE GLIOMA. Neuro-Oncology. 2020 Nov 9; 22(Supplement_2):ii9-ii10. Mohamed ME, Kumar KA, Hilz HS, Wang WA, Shai SA, Taylor TJ, Clarke CJ, Molinaro MA, Lee LJ, Costello CJ, Solomon SD, Phillips PJ. .
      View in: Publisher Site   Mentions:
    28. Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. Neuro Oncol. 2020 10 14; 22(10):1516-1526. Cluceru J, Nelson SJ, Wen Q, Phillips JJ, Shai A, Molinaro AM, Alcaide-Leon P, Olson MP, Nair D, LaFontaine M, Chunduru P, Villanueva-Meyer JE, Cha S, Chang SM, Berger MS, Lupo JM. PMID: 32319527; PMCID: PMC7566399.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH -mutant diffuse gliomas. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):2506-2506. Oberheim Bush ON, Yu YY, Villanueva-Meyer VJ, Grimmer GM, Hilz HS, Solomon SD, Choi CS, Mazor MT, Hong HC, Shai SA, Phillips PJ, McDermott MM, Haas-Kogan HD, Taylor TJ, Butowski BN, Clarke CJ, Berger BM, Molinaro MA, Chang CS, Costello CJ. .
      View in: Publisher Site   Mentions:
    30. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol. 2020 04 01; 6(4):495-503. Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS. PMID: 32027343; PMCID: PMC7042822.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansCells
    31. IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi121-vi121. Zhang ZM, Hilz HS, Martin MM, Hong HC, Yu YY, Bollam BS, Grimmer GM, Looney LT, Lowman LG, Ganpule GG, Phillips PJ, Shai SA, Chang CS, Clarke CJ, Taylor TJ, Butowski BN, Ann Oberheim-Bush AN, Berger BM, Aghi AM, Hervey-Jumper HS, McDermott MM, Theodosopoulos TP, Okada OH, Costello CJ. .
      View in: Publisher Site   Mentions:
    32. GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi107-vi108. Hilz HS, Hong HC, Jalbert JL, Mazor MT, Martin MM, Kumar KA, Shelton SS, Wong WK, Hayes HJ, Yu YY, Zhang ZM, Luks LT, Olson OM, Lafontaine LM, Shai SA, Bengtsson BH, Olshen OA, Molinaro MA, McDermott MM, Chang CE, Hervey-Jumper HS, Berger BM, Lim LD, Diaz DA, Lupo LJ, Phillips PJ, Chang CS, Nelson NS, Oldham OM, Costello CJ. .
      View in: Publisher Site   Mentions:
    33. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropathol. 2019 05; 137(5):851-854. Lee JC, Mazor T, Lao R, Wan E, Diallo AB, Hill NS, Thangaraj N, Wendelsdorf K, Samuel D, Kline CN, Banerjee A, Auguste K, Raffel C, Gupta N, Berger M, Raleigh DR, Shai A, Phillips JJ, Bollen AW, Tihan T, Perry A, Costello J, Solomon DA. PMID: 30877433; PMCID: PMC6483828.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    34. SURG-02. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 2018 Nov 5; 20(suppl_6):vi250-vi250. Molinaro MA, Hervey-Jumper HS, J. Han JS, Morshed MR, Lafontaine LM, Ebrahimi EN, Young YJ, J Phillips JJ, Shai SA, Warrier WG, Rice RT, Lin LY, Crane CJ, Nelson NS, Wrensch WM, Wiencke WJ, Perry PA, Ann Oberheim Bush AN, Taylor TJ, Butowski BN, Prados PM, Clarke CJ, Chang CS, Chang CE, Aghi AM, Theodosopoulos TP, McDermott MM, Berger BM. .
      View in: Publisher Site   Mentions:
    35. PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS. Neuro-Oncology. 2018 Nov 5; 20(suppl_6):vi164-vi165. Yu YY, Hilz HS, Grimmer GM, Solomon SD, Choi CS, Wahl WM, Mazor MT, Hong HC, Shai SA, J Phillips JJ, Villanueva-Meyer VJ, McDermott MM, Haas-Kogan HD, Taylor TJ, Butowski BN, Clarke CJ, Berger BM, Molinaro MA, Chang CS, Costello CJ, Oberheim Bush ON. .
      View in: Publisher Site   Mentions:
    36. NIMG-43. APPLICATION OF AN ADVANCED DIFFUSION-WEIGHTED MRI TECHNIQUE TO CHARACTERIZE GLIOMA MICROSTRUCTURE AND RELATIONSHIP TO HISTOPATHOLOGY. Neuro-Oncology. 2016 Nov 1; 18(suppl_6):vi134-vi134. Parvathaneni PP, Phillips PJ, Cabrera CJ, Shai SA, Cha CS, Chang CS, Nelson NS, Lupo LJ. .
      View in: Publisher Site   Mentions:
    37. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis. Cancer Res. 2015 Aug 01; 75(15):3167-80. Shai A, Dankort D, Juan J, Green S, McMahon M. PMID: 26001956; PMCID: PMC4526430.
      View in: PubMed   Mentions: 13     Fields:    Translation:Animals
    38. E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res. 2010 Jun 15; 70(12):5064-73. Shai A, Pitot HC, Lambert PF. PMID: 20530688; PMCID: PMC2888794.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    39. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res. 2010 Apr 01; 70(7):2924-31. Maufort JP, Shai A, Pitot HC, Lambert PF. PMID: 20332225; PMCID: PMC2848882.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    40. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009 Sep 15; 23(18):2152-65. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. PMID: 19759263; PMCID: PMC2751988.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansAnimalsCells
    41. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res. 2008 Dec 01; 68(23):9928-34. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. PMID: 19047174; PMCID: PMC2596671.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    42. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res. 2008 Apr 15; 68(8):2622-31. Shai A, Pitot HC, Lambert PF. PMID: 18413729; PMCID: PMC2862766.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    43. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 2007 Feb 15; 67(4):1626-35. Shai A, Brake T, Somoza C, Lambert PF. PMID: 17308103; PMCID: PMC2859178.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    With one click, see people who:

    Mentor Faculty

    Offer Student Projects

    Run Clinical Trials

    Work in Global Health Equity

    See more options in the Advanced Search tab

    Anny's Networks
    Concepts (130)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (52)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-2-gbbe5f151 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.